An external adviser will handle workplace misconduct claims against judges at the NSW Supreme Court under a new policy implemented following allegations that former High Court justice Dyson Heydon sexually harassed six female associates during his time on the bench.
A judge has adjourned an interlocutory application because of deficient pleadings in a class action brought against three medical device manufacturers and a former doctor on behalf of thousands of women who claim to have suffered lifelong complications from pelvic mesh implants.
A delegate of IP Australia has tossed opposition by veterinary pharmaceutical company Norbrook Laboratories to a patent by rival animal health specialist Bayer New Zealand for a bovine antiseptic treatment.
A court has appointed provisional liquidators to the IPO Wealth Group, rejecting claims by the firm’s sole director that the move would severely damage his reputation and that of the wider Mayfair group.
Daily Telegraph publisher Nationwide News has failed in its appeal of a judgment that found it defamed Geoffrey Rush in articles that accused the Oscar-winning actor of sexually inappropriate behaviour, with an appeals court describing the stories as a “sensationalised tabloid crusade”.
Former High Court Justice Dyson Heydon can no longer practice as a barrister, after an investigation conducted by the court found he sexually harassed six female associates.
Police have arrested Titus Day, the former manager of pop star Guy Sebastian, over allegations he duped the singer out of $1.15 million over seven years.
Cleaning services giant Spotless must pay redundancy entitlements to a group of workers it sacked, after failing to convince a court of appeal that it was exempt from making the payments.
The company that operates the Newmarch House nursing home in Sydney is facing a possible class action after a coronavirus outbreak at the facility resulted in the deaths of 19 residents.
Drug manufacturer Janssen wants to expand its high stakes case against Juno Pharmaceuticals over its HIV drug Prezista, alleging Juno’s plans to launch a generic version of the drug threaten another one of its patents.